A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CheckMate 714
- Sponsors Bristol-Myers Squibb
- 28 Sep 2017 Planned primary completion date changed from 25 Feb 2018 to 30 May 2018.
- 06 Sep 2017 Planned number of patients changed from 566 to 400.
- 06 Sep 2017 Planned End Date changed from 23 Oct 2019 to 17 Oct 2020.